MX2019003897A - Composiciones y metodos para el diagnostico y el tratamiento de trastornos relacionados con macrofagos que utilizan el transportador macromolecular a base de carbohidratos. - Google Patents
Composiciones y metodos para el diagnostico y el tratamiento de trastornos relacionados con macrofagos que utilizan el transportador macromolecular a base de carbohidratos.Info
- Publication number
- MX2019003897A MX2019003897A MX2019003897A MX2019003897A MX2019003897A MX 2019003897 A MX2019003897 A MX 2019003897A MX 2019003897 A MX2019003897 A MX 2019003897A MX 2019003897 A MX2019003897 A MX 2019003897A MX 2019003897 A MX2019003897 A MX 2019003897A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- diagnosing
- carbohydrate
- methods
- related disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
- A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- AIDS & HIV (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
Abstract
La presente invención se refiere a composiciones y métodos relacionados con moléculas que se dirigen a CD206 de cadena principal a base de carbohidratos. En la presente se describen composiciones para diagnosticar y tratar trastornos, por ejemplo, pero sin limitación, trastornos mediados por inflamasomas. Las composiciones descritas en la presente pueden actuar como moléculas portadoras para administrar agentes diagnósticos y terapéuticos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662404111P | 2016-10-04 | 2016-10-04 | |
PCT/US2017/055211 WO2018067751A1 (en) | 2016-10-04 | 2017-10-04 | Compositions and methods for diagnosing and treating macrophage-related disorders using carbohydrate-based macromolecular carrier |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019003897A true MX2019003897A (es) | 2019-11-18 |
Family
ID=61757465
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019003897A MX2019003897A (es) | 2016-10-04 | 2017-10-04 | Composiciones y metodos para el diagnostico y el tratamiento de trastornos relacionados con macrofagos que utilizan el transportador macromolecular a base de carbohidratos. |
Country Status (6)
Country | Link |
---|---|
US (2) | US20180092998A1 (es) |
EP (1) | EP3522938A4 (es) |
CA (1) | CA3039519A1 (es) |
IL (1) | IL265727A (es) |
MX (1) | MX2019003897A (es) |
WO (1) | WO2018067751A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111447955A (zh) * | 2017-07-21 | 2020-07-24 | 纳维迪亚生物制药有限公司 | 99mTc-替马诺塞和相关的分子构建体用于鉴定和诊断恶性肿瘤和用于监测治疗性抗肿瘤干预的用途 |
WO2022157373A1 (en) * | 2021-01-25 | 2022-07-28 | Vrije Universiteit Brussel | Compositions and kits for in vivo imaging of cardiac sarcoidosis |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ500273A (en) * | 1997-03-18 | 2001-12-21 | Nihon Schering Kabushiki Kaish | Gadolinium (Gd) polymer MRI contrast agent responsive to environmental changes |
ES2228536T3 (es) * | 1999-05-14 | 2005-04-16 | The Regents Of The University Of California | Soporte macromolecular a base de dextrano para un farmaco y suministro de un agente de diagnosotico. |
US20090311182A1 (en) * | 2004-03-31 | 2009-12-17 | Dong Wang | Macromolecular Delivery Systems for Non-Invasive Imaging, Evaluation and Treatment of Arthritis and Other Inflammatory Diseases |
US9644039B2 (en) * | 2006-03-24 | 2017-05-09 | The Regents Of The University Of California | Acid-degradable and bioerodible modified polyhydroxylated materials |
JP6607854B2 (ja) * | 2013-07-22 | 2019-11-20 | ナビディア、バイオファーマスーティカルズ、インコーポレイテッド | Cd206発現細胞関連障害を診断および処置するための組成物、方法およびキット |
CA2955441C (en) * | 2014-07-17 | 2023-03-14 | Ohio State Innovation Foundation | Dextran conjugates for targeting macrophages and other cd296-expressing cells |
CA2955438A1 (en) * | 2014-07-17 | 2016-01-21 | Ohio State Innovation Foundation | Dextran conjugates for targeting macrophages and other mannose binding c-type lectin receptor expressing cells |
US20160206763A1 (en) * | 2015-01-21 | 2016-07-21 | Navidea Biopharmaceuticals, Inc. | Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same |
-
2017
- 2017-10-04 CA CA3039519A patent/CA3039519A1/en active Pending
- 2017-10-04 WO PCT/US2017/055211 patent/WO2018067751A1/en active Application Filing
- 2017-10-04 EP EP17859145.9A patent/EP3522938A4/en active Pending
- 2017-10-04 MX MX2019003897A patent/MX2019003897A/es unknown
- 2017-10-04 US US15/724,959 patent/US20180092998A1/en not_active Abandoned
-
2019
- 2019-03-31 IL IL265727A patent/IL265727A/en unknown
-
2020
- 2020-12-10 US US17/118,224 patent/US20210338848A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2018067751A1 (en) | 2018-04-12 |
US20180092998A1 (en) | 2018-04-05 |
EP3522938A4 (en) | 2020-06-24 |
IL265727A (en) | 2019-05-30 |
CA3039519A1 (en) | 2018-04-12 |
US20210338848A1 (en) | 2021-11-04 |
EP3522938A1 (en) | 2019-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201692201A1 (ru) | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 | |
MX2023000745A (es) | Composiciones para usarse en el suministro de agentes biomacromoleculares. | |
MX2017013562A (es) | Reguladores de microbioma y usos relacionados de los mismos. | |
EA201890908A1 (ru) | Композиции и способы для лечения мышечной дистрофии дюшенна и сходных нарушений | |
EA201692177A1 (ru) | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 | |
MX2017004838A (es) | Composiciones de interleucina-15 y usos de estas. | |
MX2018000352A (es) | 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b. | |
PH12019502363A1 (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
MX2017001971A (es) | Composiciones antimetanogenicas y sus usos. | |
EA201691541A1 (ru) | Новые анти-baff антитела | |
MX2020006237A (es) | Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4. | |
PH12018502137A1 (en) | Anti-complement factor bb antibodies and uses thereof | |
MX356755B (es) | Compuestos de tipo fumagilol y metodos para su elaboración y uso. | |
MX2019013808A (es) | Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer. | |
PH12019501224A1 (en) | Compositions for treatment of polycystic kidney disease | |
GB201213484D0 (en) | Pharmaceutical compositions comprising 15-OHEPA and methods of using the same | |
PH12016501613B1 (en) | Pyrazines modulators of gpr6 | |
TW201713686A (en) | Methods for preparing modified von Willebrand factor | |
MX2019003897A (es) | Composiciones y metodos para el diagnostico y el tratamiento de trastornos relacionados con macrofagos que utilizan el transportador macromolecular a base de carbohidratos. | |
WO2018045078A3 (en) | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING LYMPHATIC SYSTEM DISORDERS | |
MX2018012545A (es) | Reactivos para el tratamiento de distrofia muscular oculofaríngea (opmd) y su uso. | |
MX2021007271A (es) | Nuevas moleculas de acido nucleico conjugado y sus usos. | |
MX2020002585A (es) | Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer. | |
MX2020002147A (es) | Composiciones útiles para la mejora del dolor. | |
PH12017500500A1 (en) | C-20 steroid compounds, compositions and uses thereof to treat traumatic brain injury (tbi), including concussions |